Your browser doesn't support javascript.
loading
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.
Wang, Xiaohong; Schoenhals, Jonathan E; Li, Ailin; Valdecanas, David R; Ye, Huiping; Zang, Fenglin; Tang, Chad; Tang, Ming; Liu, Chang-Gong; Liu, Xiuping; Krishnan, Sunil; Allison, James P; Sharma, Padmanee; Hwu, Patrick; Komaki, Ritsuko; Overwijk, Willem W; Gomez, Daniel R; Chang, Joe Y; Hahn, Stephen M; Cortez, Maria Angelica; Welsh, James W.
Afiliação
  • Wang X; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Schoenhals JE; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Li A; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Valdecanas DR; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ye H; Department of Otolaryngology Head and Neck Surgery, The Affiliated Baiyun Hospital of Guiyang Medical University, Guiyang Medical University, Guiyang, China.
  • Zang F; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tang C; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tang M; Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Liu CG; Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Liu X; Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Krishnan S; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Allison JP; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sharma P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hwu P; Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Komaki R; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Overwijk WW; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gomez DR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Chang JY; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hahn SM; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Cortez MA; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Welsh JW; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. jwelsh@mdanderson.org.
Cancer Res ; 77(4): 839-850, 2017 02 15.
Article em En | MEDLINE | ID: mdl-27821490
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transdução de Sinais / Interferon Tipo I / Receptor de Morte Celular Programada 1 / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transdução de Sinais / Interferon Tipo I / Receptor de Morte Celular Programada 1 / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2017 Tipo de documento: Article